Gliomas are the most common type of malignant primary intracranial tumors and account for almost 80% of primary malignant brain tumors. Despite multimodal aggressive treatment, which consists of resection, local radiotherapy, and systemic chemotherapy, the prognosis of gliomas is still unsatisfying. Targeting endothelial cells (ECs) was a major focus of antiangiogenic therapeutics, which was considered the most promising treatment in past years. However, most current therapies that target glioma ECs have been proven to be effect-limited. On the contrary, some experts hold that, to some extent, they may transform tumor growth patterns toward a more invasive phenotype.

The most widely used antiangiogenic drug for gliomas—bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor A ligand—has not reached the expected clinical effect. Therefore, in order to pursue optimal antiangiogenic benefits, further insights into glioma vascular development and maintenance would have profound translational implications.

In the present study, for the first time, we found that the ECs of oligodendroglial tumors also harbored 1p/19q co-deletion, which was a recognized molecular biomarker for oligodendroglial tumor cells. These findings implied that ECs and tumor cells in gliomas shared a common pathway in tumor genesis. Here, we propose a hypothesis that ECs might differentiate from the glioma stem cells of anaplastic oligodendroglioma (AO). This seems to be a new perspective in glioma biology.

**Abbreviations**
- AO = anaplastic oligodendroglioma
- DAPI = diamidino-2-phenylindole
- EC = endothelial cell
- FISH = fluorescence in situ hybridization
- KPS = Karnofsky Performance Scale
- OS = overall survival
- PBS = phosphate-buffered saline
- PFS = progression-free survival
- ROC = receiver operating characteristic
perspective toward the mechanism of angiogenesis and chemosensitivity of oligodendrogial tumors. This study was designed to explore the origin of ECs in 1p/19q–co-deleted AO and evaluate the prognostic significance of 1p/19q co-deletion in ECs.

Methods

Ethics Statement
Records from a series of 30 patients with a histological diagnosis of primary AO and high rates of 1p/19q co-deletion in the tumor cells between January 2009 and January 2010 were retrospectively retrieved from the pathology files of our department. This study was performed according to the standards of the institutional ethics committee and the Helsinki Declaration of 1975, as revised in 1983, and approved by the institutional review board of Capital Medical University.

Pathological Examination
Fresh paraffin-embedded tumor tissues were sectioned into 4-μm-thick slides and stained with hematoxylin and eosin. All specimens were independently reviewed by 3 experienced neuropathologists (Jumei Wang, Guang Li, and Lin Luo), who were blinded to the clinical outcomes of the patients, according to the 2007 WHO classification for central nervous system tumors. In the case of a discrepancy, the 3 observers simultaneously reviewed the slides in order to achieve a consensus, and the corresponding immunohistochemical staining would be performed if necessary.

Follow-Up
Patients who underwent needle biopsies prior to resection and/or prior adjuvant therapy (radiotherapy or chemotherapy) were excluded from the analysis. This was done to create a more uniform patient population that could be propitious to the study. Progression-free survival (PFS) was designated as the time from the first operation to the time of tumor recurrence or evidence of progression on MRI. Overall survival (OS) was defined as the period between the first operation and death. The patients were followed up for 29.0 to 61.0 months after surgery, and the median follow-up was 42.0 months.

Treatment
All patients enrolled in the present study were treated according to the latest National Comprehensive Cancer Network guideline. Once pathologically diagnosed with AO, patients received systematic chemotherapy and radiotherapy after the operation. Postoperative radiotherapy was delivered to patients within 1 month after the operation. The total dose was 60 Gy, which was divided into 30 daily fractions of 2 Gy each. Meanwhile, postoperative chemotherapy was given: the common course of chemotherapy was 4 to 6 cycles, which depended on the tolerance of toxic effects. The adjuvant chemotherapy drug was mainly nimustine.

Immunofluorescence
The 4-μm-thick slides were deparaffinized and dehydrated. Sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) was added to a microwaveable vessel, and the slides were conveniently put into the microwaveable vessel. Then, we put the vessel into a microwave that was set to full power. After the solution-containing vessel was boiled for 20 minutes in the microwave, the vessel was taken out and cooled to room temperature. The slides were washed 3 times, for 3 minutes each time, in phosphate-buffered saline (PBS) with gentle agitation and then blocked in 1% bovine serum albumin for 2 hours at room temperature. After draining for a few seconds and wiping with tissue paper, the slides were incubated with the primary antibody—mouse anti-CD34 (dilution 1:100; ZM-0046, Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd)—at 4°C overnight. Then, the slides were washed 5 times, for 3 minutes each time, in PBS with gentle agitation and incubated with the secondary antibody—rhodamine-conjugated AffiniPure goat anti–mouse IgG (1:100; ZF-0313, Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd)—at 37°C for 2 hours. Next, the slides were rinsed 3 times, for 3 minutes each, in PBS with gentle agitation and incubated with diamidino-2-phenylindole (DAPI) at 37°C for 2 minutes for fluorescent detection. The last 3 steps should be done in the dark. Fluorescence was observed using an Olympus BX51TRF microscope (Olympus) (Fig. 1A).

Fluorescence in Situ Hybridization
The 1p/19q fluorescent probe kit (Vysis) was used for the fluorescence in situ hybridization (FISH) test. Briefly, the 4-μm-thick paraffin slides were deparaffinized, dehydrated, and incubated in 1 mol/L NaSCN for 35 minutes at 80°C. The slides were then immersed in a pepsin solution (0.65% in protease buffer with 0.01 mol/L HCl) for 10 minutes at 37°C, and the tissues were fixed in 10% neutral buffered formalin. Then, the specimens were dehydrated in ethanol (70%, 85%, and 100% for 2 minutes in each bath), and air dried; 20 μl of each probe was then added separately, and the slides were sealed with rubber cement. After co-denaturation for 10 minutes at 75°C, the slides were then put in a humidified atmosphere with Hybrite (ThermoBriteTM; Vysis) for 16 hours at 37°C. The slides were first immersed in 2× salt-sodium citrate/0.3% NP-40 for 2 minutes at room temperature and then in 2× salt-sodium citrate/0.3% NP-40 for 2 minutes at 73°C. After drying, the nuclei were counterstained with 4,6-DAPI and an anti-fade compound (p-Phenylenediamine). The FISH signals for each locus-specific FISH probe were assessed under an Olympus BX51TRF microscope (Olympus) equipped with a triple-pass filter (DAPI/green/orange; Vysis) (Fig. 1B).

The assessment and interpretation of the FISH results were made according to the guidelines defined by the International Society of Paediatric Oncology’s (SIOP) European Neuroblastoma Pathology and Biology and Bone Marrow Group. For each probe, more than 100 nonoverlapping nuclei were enumerated per hybridization. The tumor cells with more than 30% of the nuclei showing DNA loss were defined as tumor cells with chromosomal loss. According to the results of the receiver operating characteristic (ROC) curve analysis (Fig. 2), we designed the...
1p/19q co-deletion in ECs confers favorable outcome

vascular ECs with more than or equal to 15% of nuclei showing DNA loss as ECs with 1p/19q deletion, while those with less than 15% were defined as 1p/19q intact.

**Statistical Analysis**

The statistical analysis was performed using SPSS 13.0 for Windows. Survival function concerning the 1p/19q deletion status of the vascular ECs was assessed using the Kaplan-Meier estimate and log-rank test. The paired-sample t-test was used to compare the 1p/19q deletion rate between 1p36 and 1q25 or 19q13 and 19p13. The p value was obtained using 2-sided tests with a statistical significance of p < 0.05. The appropriate 1p/19q deletion cutoff values for vascular ECs for distinguishing long-term survivors from short-term survivors were designed according to the area under the ROC curve. Generally, an area under the ROC curve ≥ 0.70 was considered a clinically useful predictive model.

**Results**

**Basic Characteristics**

The basic clinical characteristics of the patients enrolled in this study are summarized in Table 1. A total of 30 patients with a diagnosis of primary AO who were surgically treated at our center were included in the present study. There were 16 male and 14 female patients with a median age of 46.5 years (range 23–61 years). The median Karnofsky Performance Scale (KPS) score of this cohort was 90 (range 70–100).

Gross-total resection was achieved in 21 (70.0%) patients, subtotal resection in 8 (26.7%) patients, and partial resection in 1 (3.3%) patient.

There were 15 (50.0%) AOs located in the frontal lobe, 12 (40.0%) in the temporal lobe, 2 (6.7%) in the parietal lobe, and 1 (3.3%) in the insular cortex.

**1p/19q Co-Deletion in the Vascular ECs of AO**

For each case, the tissue was cut into 4-µm-thick serial sections. We chose 1 slide for immunofluorescence detection in order to locate the ECs (Fig. 1A), while another slide close to it was chosen for FISH detection with the aim of evaluating 1p/19q status (Fig. 1B).

The ECs in AO had a higher 1p36 (the detected signal) deletion rate than 1q25 (the reference signal) (p < 0.01)
and a higher 19q13 (the detected signal) deletion rate than 19p13 (the reference signal) (p < 0.01) (Table 2).

We performed ROC analysis to determine the accuracy of using 15% as the cutoff for 1p/19q deletion in ECs (Fig. 2). Meanwhile, the median PFS and OS of the whole cohort enrolled in this study were 35.0 months and 42.0 months, respectively. Therefore, recurrence at 35 months and death at 42 months were selected to serve as observation points. The ROC curves for 1p/19q deletion were plotted. We observed clear separations between the groups of patients with a 1p/19q deletion rate ≥15% in ECs and those with a 1p/19q deletion rate < 15% in ECs with respect to both PFS and OS, with areas under the curve of 0.924 (95% CI 0.791–1.000) for PFS and 0.863 (95% CI 0.714–1.000) for OS. Corresponding to this analysis, the cutoff 1p/19q deletion rate with the highest accuracy for both PFS and OS was determined as follows: 1p/19q deletion rate of 15% with 83.3% sensitivity and 100.0% specificity for PFS, and 1p/19q deletion rate of 15% with 75.0% sensitivity and 94.4% specificity for OS (Fig. 2). According to our specific co-deletion criteria, the patients could be divided into long-term survivors and short-term survivors, and 10 of 30 (33.3%) patients exhibited 1p/19q co-deletion in ECs.

Prognostic Implication of 1p/19q Co-Deletion in Vascular ECs

1p/19q co-deletion in ECs was associated with longer PFS and OS. Patients who harbored 1p/19q–co-deleted ECs demonstrated recurrence with a median PFS of 44.0 months, which was significantly longer than those with 1p/19q-intact ECs (p < 0.001). Furthermore, patients who harbored 1p/19q–co-deleted ECs died at a median OS of 52.0 months, which was significantly longer than those with 1p/19q-intact ECs (p < 0.001). Our results were validated in an independent cohort that contained 30 AO samples from the Beijing Neurosurgical Institute. According to the 1p/19q deletion rate of the ECs, the samples of the
1p/19q co-deletion in ECs confers favorable outcome

**TABLE 2.** The 1p/19q deletion rate of vascular ECs in AO

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Subgroup 1</th>
<th>Subgroup 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1q25 Deletion Rate (%)</td>
<td>1p36 Deletion Rate (%)</td>
</tr>
<tr>
<td>1</td>
<td>4</td>
<td>17</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>19</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>26</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>17</td>
</tr>
<tr>
<td>6</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>16</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>12</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>17</td>
</tr>
<tr>
<td>11</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>12</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>13</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>14</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>15</td>
<td>2</td>
<td>22</td>
</tr>
<tr>
<td>16</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>17</td>
<td>9</td>
<td>13</td>
</tr>
<tr>
<td>18</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>19</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>20</td>
<td>1</td>
<td>10</td>
</tr>
<tr>
<td>21</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>22</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>23</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>24</td>
<td>4</td>
<td>15</td>
</tr>
<tr>
<td>25</td>
<td>15</td>
<td>15</td>
</tr>
<tr>
<td>26</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>27</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>28</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>29</td>
<td>7</td>
<td>21</td>
</tr>
<tr>
<td>30</td>
<td>0</td>
<td>26</td>
</tr>
</tbody>
</table>

p value <0.01 <0.01

independent validation cohort were divided into 2 groups: 1p/19q deletion rate ≥ 15% (i.e., 1p/19q co-deletion) and 1p/19q deletion rate < 15% (i.e., 1p/19q intact). The results of the survival analysis of the 2 groups demonstrated that there was a statistically significant difference in prognosis (p < 0.001 for PFS and p = 0.003 for OS) (Fig. 3).

In a multivariate Cox regression model that included age, KPS, degree of tumor resection, and 1p/19q status, 1p/19q codeletion in ECs was confirmed as an independent prognostic factor and was associated with both longer PFS and OS. The hazard ratio of 1p/19q co-deletion in ECs was 0.056 (95% CI 0.013–0.280; p < 0.001) for PFS and 0.061 (95% CI 0.013–0.280; p < 0.001) for OS.

**Discussion**

It has been well established that 1p/19q co-deletion is a genetic marker for oligodendroglial tumors and confers favorable chemosensitivity and prognosis. In 1998, Cairncross et al. reported that the loss of 1p and/or 1p/19q co-deletion predicted a better response to procarbazine-lomustine-vincristine chemotherapy and a longer survival time in patients with AO.2 These findings have been reproduced in many subsequent studies, including prospective and randomized Phase III clinical trials.2,18 However, the prognostic significance of 1p/19q co-deletion was elaborated on the basis of a theory that the existence of 1p/19q co-deletion was found only in tumor cells. In other words, 1p/19q co-deletion was a tumor cell–specific biomarker. However, in the present study, we found some ECs in AO possessed this chromosomal abnormality as well. Furthermore, 1p/19q co-deletion in ECs also conferred a longer survival time. This might be a new perspective toward the vascular development and maintenance of malignant gliomas.

**Vascular ECs Might Be Derived From Glioma Stem Cells**

The formation of blood vessels in glioma is extremely complicated. It has been reported that glioma stem cells could differentiate into vascular ECs, which assemble to form a vascular plexus that could support blood cell circulation and mature into a vascular network.6 Using the patients’ surgical specimens, Wang et al.17 and Ricci-Vitiani et al.13 found a subset of ECs lining the tumor vessels that carried the same genetic abnormalities (e.g., amplification of epidermal growth factor receptor or TP53 mutation), which were exclusive markers of adjacent malignant tumor cells. These 2 research groups both showed that a subpopulation of glioma stem cells could give rise to endothelial cells in vitro. These cells, when intracranially transplanted into immunocompromised mice, could give rise to tumors. Further research confirmed that in these tumors there was a proportion of ECs that contributed to blood vessels and originated from the transplanted human glioma cells rather than from mice. Soda et al.15 observed a subpopulation of ECs within these tumors that could express both EC-specific and tumor-specific antigens.

In the present study, we revealed that 1p/19q co-deletion, which was initially regarded as a tumor cell–specific chromosomal abnormality, could also be found in ECs. However, not all (100%) ECs contained the 1p/19q deletion signature. This was consistent with Streubel and colleagues’ report, which found that 15% to 85% (median 37%) of the microvascular ECs in B-cell lymphomas harbored lymphoma-specific chromosomal translocations.16 All of these findings implied that the ECs and tumor cells in gliomas share a common pathway in tumorigenesis. Perhaps in the process of glioma stem cells differentiating into ECs and tumor cells, this genetic signature was delivered at the same time. As for the phenomenon that some ECs did not appear to exhibit 1p/19q deletion, the sectioning of tumor samples from different directions, to some extent, could influence the experimental results, especially when judging the 1p/19q status of the small vessels, which could partly contribute to it.

**1p/19q Co-Deletion in ECs Conferred a Favorable Prognosis**

The 1p/19q deletion rate in ECs was relatively lower
than that in tumor cells. According to the results of the ROC analysis, we defined the cutoff of 15% as the criterion for 1p/19q deletion in ECs. Therefore, in this study, 10 of 30 (33.3%) 1p/19q–co-deleted AOs exhibited 1p/19q co-deletion in ECs.

Our study, for the first time, interpreted that the survival time of patients with 1p/19q–co-deleted ECs is significantly longer than those with 1p/19q-intact ECs, which was further validated in an independent cohort. Although 1p/19q co-deletion is a well-known genetic marker of favorable clinical outcome, all of those former results were only elaborated in tumor cells. The favorable clinical outcomes of patients with 1p/19q–co-deleted tumor cells resulted from relatively better chemosensitivity and radiosensitivity.2,18 As for the patients with 1p/19q co-deleted ECs, the reasons for the prognosis advantage require further inquiry.

Potential Mechanism of Resistance to Antiangiogenesis Therapy

According to the FISH detection results, 20 (66.7%) of 30 patients had 1p/19q-intact ECs, which conferred a dismal prognosis. Perhaps the dismal prognosis of this subgroup was attributable to the limited sensitivities of 1p/19q-intact ECs to therapies, including chemotherapy and antiangiogenesis treatment. With regard to the compromised effectiveness of antiangiogenesis therapy, Cheng et al.4 found that glioma stem cells could also generate some vascular pericytes that surrounded blood vessels within the glioblastoma multiforme. Furthermore, they observed that the majority of vascular pericytes carried the same genetic alterations, which were found in the glioblastoma multiforme. These findings had important implications for glioblastoma therapy: increased pericyte coverage was thought to have conferred resistance to bevacizumab.

In our previous studies, we have found that 1q and/or 19p polysomy in the tumor cells of glioma showed an unfavorable outcome.5,12 According to the FISH detection results, we noted that the tumor cell–specific chromosomal aberrations (1q and 19p polysomy) also occurred in the ECs (Fig. 1). In 2004, Streubel et al.16 reported that numerical chromosomal aberrations were shared by lymphoma cells and ECs. As we all know, polysomy was always treated as a consequence of increased genetic instability and cell-cycle dysregulation, which might lead to increased copy numbers of chromosomes and then correlate with tumor progression. Therefore, the existence of ECs harboring polysomy might be another potential reason for resistance to antiangiogenesis drugs. But, this idea remains to be elucidated in future research.

Study Limitations

Some limitations existed in this study. There were only 30 patients in this series, which is not so large. Besides, the potential molecular mechanisms of 1p/19q co-deletion in ECs associated with favorable prognosis have not been disclosed. In the future, we will expand the sample and continue carrying out this research.

Conclusions

1p/19q co-deletion and polysomy are shared by tumor cells and ECs in AO. Our findings suggest that vascular ECs in AO are, in part, tumor related, which points to a novel aspect of tumor angiogenesis.

Acknowledgments

We acknowledge financial support by Beijing Natural Science Foundation (7122061), National Natural Science Foundation of China (81401381), and the Capital Health Research and Development Special Fund (2014-2-2042). We thank Dr. Lin Luo for providing pathological diagnoses, Department of Pathology, Beijing Neurosurgical Institute; and Dr. Guang Li, Department of Pathology, Beijing Tiantan Hospital, Capital Medical University.

References


Disclosures

The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions

Conception and design: Jiang. Acquisition of data: Zhang, Zeng. Analysis and interpretation of data: Zhang. Drafting the article: Jiang. Critically revising the article: Ren. Reviewed submitted version of manuscript: Ren. Approved the final version of the manuscript on behalf of all authors: Lin. Statistical analysis: Zeng. Administrative/technical/material support: Wang. Study supervision: Lin.

Correspondence

Song Lin, Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Chongwen District, Beijing 100050, China. email: linsong2005@126.com.